{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-276899","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.251556+00:00","generated_at":"2026-06-22T09:45:23.911516+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nuvation Bio Q3 net loss $27.2M; cash $673.9M; NUV-868 Phase 1b on track","bullets":["Net loss of $27.2M ($0.12/share) vs $22.0M ($0.11/share) in Q3 2021.","Cash, cash equivalents and marketable securities of $673.9M as of Sep 30, 2022; runway through 2028.","R&D expenses $21.3M (incl. $1.6M restructuring and $5.7M contract termination costs).","Phase 1 monotherapy of NUV-868 dosing; Phase 1b combo with olaparib/enzalutamide expected by end of 2022.","DDC platform first clinical candidate nomination on track for end of 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-276899","json":"https://secwatch.observer/filing/0001193125-22-276899.json","markdown":"https://secwatch.observer/filing/0001193125-22-276899.md","text":"https://secwatch.observer/filing/0001193125-22-276899.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312522276899/0001193125-22-276899-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312522276899/d410431d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:45:23.911516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd9b31028d40a5951c6edd629f473c732b56abb7","claim":"Nuvation Bio Inc. reported the third quarter ended September 30, 2022 results: net income net loss of $27.2 million, or $(0.12) per share, EPS $(0.12) per share.","evidence_excerpt":"For the three months ended September 30, 2022, Nuvation Bio reported a net loss of $27.2 million, or $(0.12) per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312522276899/0001193125-22-276899-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"net loss of $27.2 million, or $(0.12) per share"},{"label":"EPS","value":"$(0.12) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}